How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy

Annals of Pharmacotherapy

Volumn 40, Issue 6, 2006, Pages 1143-1150

  Gold, Deborah T ^a   Alexander, Ivy M ^b   Ettinger, Mark P ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b YALE UNIVERSITY   (United States)

^c RADIANT RESEARCH   (United States)

Author keywords

Adherence; Fracture; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADVERSE DRUG REACTION; ATTITUDE TO ILLNESS; BONE TURNOVER; CLINICAL TRIAL; CONTINUING EDUCATION; DIAGNOSTIC ERROR; DRUG COST; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; FOLLOW UP; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEARTBURN; HUMAN; INFORMATION RETRIEVAL; MEDLINE; NAUSEA; OSTEOPOROSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT PARTICIPATION; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; STOMACH PAIN; SURGEON; THERAPEUTIC ERROR; UNDERDIAGNOSIS; UNDERTREATMENT; VOCATIONAL EDUCATION;

ADULT; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PATIENT EDUCATION;

EID: 33745069049     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G534     Document Type: Review

References (72)

1. America's bone health: the state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation, 2002.
2. Melton LJ 3rd. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003;18:1139-41.
3. Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General, 2004.
4. Siris ES, Bilezikian JP, Rubin MR, et al. Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab 2003;88:3482-6. DOI 10.1210/jc.2003-030568
5. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16. DOI 10.1016/S0002-9343(03) 00362-0
6. Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975;13:10-24.
7. Pickney CS, Arnason JA. Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int 2005;16:1156-60. Epub 3 Mar 2005. DOI 10.1007/s00198-004-1818-8
8. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61.
9. Lombas C, Hakim C, Zanchetta J. Compliance with alendronate treatment in an osteoporosis clinic (abstract M406). J Bone Miner Res 2001;15(suppl):S529.
10. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87. DOI 10.1016/j.maturitas.2004.02.005
11. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60. DOI 10.185/030079905X61875
12. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8. DOI 10.1007/s00198-004-1652-z
13. Siris E, Rosen C, Harris S, Abbott T, Barr C, Silverman S. Adherence rates to bisphosphonate therapy: relationship to bone fractures at 24 months in women with postmenopausal osteoporosis. Washington, DC: National Osteoporosis Foundation, 2005.
14. Sebaldt R, Shane L, Pham B, et al. Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis (abstract M23). J Bone Miner Res 2004;19(suppl 1):S445.
15. Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study (abstract). Calcif Tissue Int 2003;72:408.
16. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-8. DOI 10.1007/s00198-003-1502-4
17. Emkey R, Delmas PD, Goemaere S, et al. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study. Arthritis Rheum 2003;48:1102-8. DOI 10.002/art.10861
18. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone Epub 1 Dec 2005.
19. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414-9.
20. Prevention and management of osteoporosis. World Health Organization technical report series 921. Geneva: World Health Organization, 2003:1-164.
21. Fact sheet: osteoporosis overview. Osteoporosis and related bone diseases-National Resource Center. Washington, DC: National Institutes of Health, 2003.
22. Gold DT, Shipp KM, Pieper CF, Duncan PW, Martinez S, Lyles KW. Group treatment improves trunk strength and psychological status in older women with vertebral fractures: results of a randomized, clinical trial. J Am Geriatr Soc 2004;52:1471-8. DOI 10.1111/j.1532-5415.2004.52409.x
23. Solomon CG. Bisphosphonates and osteoporosis. N Engl J Med 2002;346:642.
24. Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. Rheum Dis Clin North Am 2001;27:255-62.
25. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK. The components of excess mortality after hip fracture. Bone 2003;32:468-73. DOI 10.1016/S8756-3282(03)00061-9
26. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. DC: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8. DOI 10.1210/er.2001-9002
27. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
28. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
29. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2003.
30. US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002;137:526-8.
31. Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int 1993;3:120-6.
32. Melton LJ 3rd. Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res 2000;15:2309-14.
33. Simonelli C, Chen YT, Morancey J, Lewis AF, Abbott TA. Evaluation and management of osteoporosis following hospitalization for low-impact fracture. J Gen Intern Med 2003;18:17-22.
34. Follin SL, Black JN, McDermott MT. Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy 2003;23:190-8.
35. Hajcsar EE, Hawker G, Bogoch ER. Investigation and treatment of osteoporosis in patients with fragility fractures. CMAJ 2000;163:819-22.
36. Gardner MJ, Flik KR, Mooar P, Lane JM. Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surg Am 2002;84-A:1342-8.
37. Gunter MJ, Beaton SJ, Brenneman SK, Chen YT, Abbott TA 3rd, Gleeson JM. Management of osteoporosis in women aged 50 and older with osteoporosis-related fractures in a managed care population. Dis Manag 2003;6:83-91.
38. Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002;162:2217-22.
39. Harrington JT, Broy SB, Derosa AM, Licata AA, Shewmon DA. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum 2002;47:651-4. DOI 10.1002/art.10787
40. Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003;163:2165-72.
41. Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003;163:2052-7.
42. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001;286:2815-22.
43. Feldstein AC, Nichols GA, Elmer PJ, Smith DH, Aickin M, Herson M. Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg Am 2003;85-A:2294-302.
44. Summers KM, Brock TP. Impact of pharmacist-led community bone mineral density screenings. Ann Pharmacother 2005;39:243-8. Epub 21 Dec 2004. DOI 10.1345/aph.1E321
45. Naunton M, Peterson GM, Jones G. Pharmacist-provided quantitative heel ultrasound screening for rural women at risk of osteoporosis. Ann Pharmacother 2006;40:38-44. Epub 22 Nov 2005. DOI 10.1345/aph.1G208
46. MacLaughlin EJ, MacLaughlin AA, Snella KA, Winston TS, Fike DS, Raehl CR. Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy 2005;25:379-86.
47. Urquhart J, De Klerk E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med 1998;17:251-67; discussion 387-9.
48. Li WW, Kendler DL. Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information. J Clin Pharm Ther 2004;29:531-6.
49. Meadows LM, Mrkonjic LA, Lagendyk LE, Petersen KM. After the fall: women's views of fractures in relation to bone health at midlife. Women Health 2004;39:47-62. DOI 10.1300/J013v39n02_04
50. Ailinger RL, Emerson J. Women's knowledge of osteoporosis. Appl Nurs Res 1998;11:111-4. DOI 10.1016/S0897-1897(98)80102-X
51. Gold DT, Silverman SL. Osteoporosis self-management: choices for better bone health. South Med J 2004;97:551-4.
52. Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA 2002;288:2469-75.
53. Jamal SA, Ridout R, Chase C, Fielding L, Rubin LA, Hawker GA. Bone mineral density testing and osteoporosis education improve lifestyle behaviors in premenopausal women: a prospective study. J Bone Miner Res 1999;14:2143-9.
54. Rolnick SJ, Kopher R, Jackson J, Fischer LR, Compo R. What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting? Menopause 2001;8:141-8.
55. Kulp JL, Rane S, Bachmann G. Impact of preventive osteoporosis education on patient behavior: immediate and 3-month follow-up. Menopause 2004;11:116-9.
56. McCormack JP, Dolovich L, Levine M, et al. Providing evidence-based information to patients in general practice and pharmacies: what is the acceptability, usefulness and impact on drug use? Health Expect 2003;6:281-9.
57. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141-51.
58. Delmas PD, Recker RR, Chesnut CH 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8. DOI 10.1007/s00198-004-1602-9
59. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1-12.
60. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11. DOI 10.1007/s00223-002-2011-8
61. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-92.
62. Simonelli C, Killeen K, Mehle S, Swanson L. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 2002;77:334-8. DOI 10.1046/j.525-497.2003.20387.x
63. Gourlay M. Osteoporosis management: out of subspecialty practice and into primary care. Am Fam Physician 2004;70:1219-20.
64. Jaglal SB, McIsaac WJ, Hawker G, et al. Information needs in the management of osteoporosis in family practice: an illustration of the failure of the current guideline implementation process. Osteoporos Int 2003;14:672-6. DOI 10.1007s00198-003-1421-4
65. Law AV, Shapiro K. Impact of a community pharmacist-directed clinic in improving screening and awareness of osteoporosis. J Eval Clin Pract 2005;11:247-55.
66. Simon J, Beusterien K, Leidy NK, Hebborn A. Women with postmenopausal osteoporosis express a preference for once-monthly versus once-weekly bisphosphonate treatment. Female Patient 2005;30:31-6.
67. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004;15:423-33. DOI 10.1007/s00198-004-1612-7
68. Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9. DOI 10.359/JBMR.040325
69. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-22. Epub 15 March 2005. DOI 10.1359/JBMR.050313
70. Recker R, Reid D, Sambrook P, Hughes C, Bonvoisin B, Adami S. Intermittent intravenous ibandronate injection regimens provide at least equivalent efficacy to daily oral ibandronate: 1-year results from DIVA (abstract L3/518). Arthritis Rheum 2004;50(suppl):4095.
71. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003;14:801-7. DOI 10.1007/s00198-003-1425-0
72. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.